A new thrombectomy catheter has been specifically designed to treat deep vein thrombosis (DVT) in large-diameter upper and lower peripheral veins.

The AngioJet ZelanteDVT thrombectomy catheter is indicated for the disruption and removal of large venous clot burdens from iliofemoral and lower extremity veins greater than or equal to 6 mm in diameter, and upper extremity peripheral veins greater than or equal to 6 mm in diameter. The 8 F (2.7 mm) catheter is the largest and strongest thrombectomy catheter in the AngioJet portfolio, with four times the thrombus removal power of previous generation catheters, and is used in conjunction with the AngioJet Ultra Console.

The 105 centimeters long thrombectomy catheter, which utilizes an over-the-wire guidewire and sheath for delivery, is torqueable and directional, enabling rapid thrombus removal, and is also PowerPulse enabled for the infusion of physician-specified fluids, including thrombolytic agents into the peripheral vascular system. The AngioJet ZelanteDVT thrombectomy catheter is a product of Boston Scientific (Natick, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“The new features of the ZelanteDVT catheter represent our focus on improving procedural efficiencies and reducing the economic burden associated with this challenging condition,” said Jeff Mirviss, peripheral interventions president at Boston Scientific. “With this addition to our AngioJet portfolio, we are further evolving the current suite of life-changing therapeutic options available to physicians and their patients with deep vein thrombosis.”

DVT commonly affects peripheral veins (such as the femoral vein, the popliteal vein, or the iliofemoral vein), and can occur without any symptoms. In many cases the affected extremity will be painful, swollen, red, and warm, and the superficial veins may be engorged. The most serious complication of a DVT is that the clot could dislodge and cause a pulmonary embolism (PE). DVT is a medical emergency and untreated lower extremity DVT has a 3% PE-related mortality rate.

Related Links:
Boston Scientific